Low molecular weight heparin for VTE treatment
Low molecular weight heparin dosage regimens to treat VTE are:
1dalteparin (CrCl 30 mL/min or more) 200 units/kg subcutaneously, once daily, or 100 units/kg twice daily1 dalteparin dalteparin dalteparin
OR
1enoxaparin enoxaparin enoxaparin enoxaparin
CrCl 30 mL/min or more: 1.5 mg/kg subcutaneously, once daily, or 1 mg/kg twice daily
CrCl less than 30 mL/min: 1 mg/kg subcutaneously, once daily.
If dalteparin is required for a patient with a CrCl of less than 30 mL/min, seek expert advice.
The twice-daily dosage regimens of dalteparin and enoxaparin may be preferred to the once-daily regimens for patients at high risk of bleeding, such as patients who are older, are at extremes of weight (eg 150 kg or over) or have cancer.
For duration of anticoagulant therapy to treat VTE, see Duration of anticoagulant therapy for VTE.
See also Parenteral anticoagulants for VTE prophylaxis and treatment in patients with obesity (if applicable) and Practical information on using low molecular weight heparin for more information, including management of bleeding.